Therapeutic areas

The ANXV journey towards helping patients begins in the eye

ANXV has the potential of being used broadly in medicine - as a therapeutic agent, as a carrier for other therapeutic agents, and in molecular imaging. The therapeutic potential of ANXV is broad within several indications in different therapeutic areas. However, our first step is to investigate ANXV´s potential effect in the eye disease retinal vein occlusion.

Therapeutic areas and clinical studies

Focus areas for development

ANXV is an investigational new drug, and its mode of action is expected to be beneficial for treating both Retinal Vein Occlusion (RVO) and cancer. ANXV is currently being investigated in a Phase 2 study for RVO, a disease that causes vision impairment or blindness in millions of patients every year.

Scroll Arrow

ANXV and retinal vein occlusion

Retinal Vein Occlusion (RVO) is the blockage or closing of a vein in the eye. It is the second most common sight-threatening retinal vascular disorder after diabetic retinopathy. Globally, the prevalence of RVO is reported to be over 16 million cases. RVO might present with a sudden, painless loss of vision and macular oedema (ME). ANXV in RVO is being investigated in an ongoing Phase 2 study with recently diagnosed RVO patients.

Read more

ANXV and cancer

Cancer is a leading cause of death worldwide, accounting for nearly 10 million losses of life in 2020, which accounts for nearly one in six deaths. The most common cancers are those occurring in the breast, lung, colon and rectum, and prostate. There are still significant, and yet unmet, clinical needs, where ANXV could potentially fill a gap. The potential of ANXV in oncology is currently being investigated in the pre-clinical stage.

Read more

ANXV potential in Sickle Cell Disease

Sickle Cell Disease (SCD) is a hereditary disease which affects the red blood cells, resulting in impaired blood supply, damage to organs, severe pain and causes premature death.

SCD patients experience frequent, painful sickle cell crises when sickle cells block blood vessels in different parts of the body. Such crises require intensive care and pain relief. There are currently no treatments that can prevent or stop these crises. However, Annexin A5 has been shown to stop ongoing sickle cell crises in animal models. If ANXV shows an effect in SCD patients, it would fill a major medical need.

ANXV potential in Cardiovascular diseases

Cardiovascular disease is the collective term for diseases that affect the heart and/or the blood vessels. It is the most common cause of death, both in Sweden and in most industrialised countries.

Common examples are myocardial infarction, peripheral occlusive arterial disease (PAOD) and stroke, often caused by atherosclerosis. Atherosclerosis is a chronic inflammatory disease of the blood vessels, and there is still no anti-inflammatory medication available to treat such conditions. However, Annexin A5 has demonstrated desirable effect in preclinical models.

Latest press releases

Se all

Annexin celebrates 10 years and the largest owner takes a seat on the board

Annexin Pharmaceuticals AB (publ) announces that it is 10 years since the company was founded with the goal of developing Annexin A5 protein into a new medicine. One of the…

Read more

Latest press releases

Se all

The subscription period in Annexin Pharmaceuticals’ rights issue begins today

NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG-KONG, JAPAN, CANADA, SINGAPORE, RUSSIA, SOUTH KOREA, SOUTH AFRICA OR NEW ZEALAND OR…

Read more

Latest press releases

Se all

Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue

NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG-KONG, JAPAN, CANADA, SINGAPORE, RUSSIA, SOUTH KOREA, SOUTH AFRICA OR NEW ZEALAND OR…

Read more

Latest press releases

Se all

Last patient treated in Annexin’s RVO study – promising signals of effect and no safety concerns

Annexin Pharmaceuticals AB today announces that the last patient has been treated with the investigational new drug ANXV in the Phase 2a study that included a total of 15 patients…

Read more